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ABSTRACT 
Background: Serum creatinine (Scr) is the major contributing variable in glomerular filtration rate 
(GFR) estimating equations. Serum cystatin C (ScysC) based GFR estimating (eGFR)-equations have 
also been developed. The present study investigates the relation between 'rescaled' levels of these 
renal biomarkers (with reference interval of [0.67-1.33]) and measured GFR (mGFR). 
Methods: We evaluated the diagnostic ability to detect impaired kidney function of the rescaled renal 
biomarkers in 8584 subjects from 12 cohorts with measured GFR, standardized Scr and ScysC. We 
calculated sensitivity and specificity of the rescaled biomarkers to identify kidney disease, with 
reference to a fixed (60mL/min/1.73m2) as well as an age-dependent threshold for mGFR. 
Results: The upper reference limit of 1.33 for rescaled renal biomarkers is closely related to the age-
dependent threshold for defining kidney status by mGFR with sensitivity and specificity for the 
rescaled biomarkers close to 90% for all ages. If the fixed threshold of 60mL/min/1.73m2for mGFR is 
used, then lower specificity in children and sensitivity in older adults are observed. 
Conclusions: Impaired kidney function can be diagnosed by rescaled renal biomarkers instead of 
eGFR-equations using the fixed threshold of 1.33 for all ages, consistent with an age-dependent 
threshold of mGFR. 
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1. INTRODUCTION 
Serum creatinine (Scr) is the most widely used renal biomarker and can be measured using assays 
that are specific (e.g. enzymatic assays) and calibrated against the reference method of isotope 
dilution mass spectrometry (IDMS). The test is relatively cheap and commonly ordered as part of a 
basic investigation panel in clinical biochemistry. However, Scr has some limitations as a renal marker: 
Scr is influenced by non-GFR determinants, e.g. muscle mass, and part of renal clearance of 
creatinine is due to tubular secretion [1]. Moreover, Scr remains within the reference interval in a 
substantial proportion of patients despite a reduced (< 60mL/min/1.73m2) glomerular filtration rate 
(GFR) [2-3] leading to doubts about Scr's ability to detect impaired kidney function [4-9]. Also, there 
are age and gender differences in creatinine generation which complicates the interpretation of Scr (as 
well as Scr-based eGFR) when assessing kidney function. For Caucasians, the determination of 
reference intervals has been the subject of detailed studies [10-11]. After birth, Scr rapidly decreases 
to a value of approximately 22µmol/L (0.25mg/dL) during the first month of life and then starts to 
increase linearly with age. Scr concentration remains constant, on average, for the healthy subject 
between 20 and 70 years of age, with a mean of 80µmol/L (0.90mg/dL) and reference interval 55.7-
102.5µmol/L (0.63-1.16mg/dL) for men and 62µmol/L (0.70mg/dL) and reference interval 42.4-
82.2µmol/L (0.48-0.93mg/dL) for women. Above the age of 70, Scr starts to slowly increase again in 
both genders [12]. 
To simplify the interpretation of Scr, Pottel et al [13-19] proposed to 'normalize' Scr. Normalization is a 
statistical term that means adjusting values measured on different scales to a notionally common 
scale. Indeed, dividing Scr with the mean Scr-value (called Qcrea) of the age and sex specific healthy 
population rescales the reference intervals to a common interval as it makes Scr/Qcrea independent of 
age/sex. Consequently the rescaled biomarker Scr/Qcrea may serve as a renal biomarker incorporating 
its limitations due to muscle mass variation, related to age and sex differences. Due to the 
'rescaling/normalizing' action, the values of Scr/Qcrea become normally distributed around the mean 
of '1' (a consequence of the definition of Qcrea) with 2.5th percentile (Pct) =0.67 and 97.5th Pct=1.33, 
(corresponding to a standard deviation of 0.1683). This holds equally true for children, adolescents 
and adults [16]. 
Serum cystatin C (ScysC) is considered a valid alternative to Scr, especially now that a certified 
reference material is available [20]. ScysC can be rescaled more easily than Scr, as ScysC is almost 
independent of age and sex [21-22]. Only in older adults we have seen a gradual but significant 
increase in ScysC-concentration with age [19], most probably due to a decline in mGFR and 
additionally influenced by non-GFR related determinants, such as cardiovascular disease risk factors 
and inflammation [23-25]. Rescaling ScysC with QcysC=0.82mg/L for children and adults up to 70 years 
and with QcysC=0.95mg/L beyond that age brings the rescaled ScysC/Qcysc to the same common 
scale as Scr/Qcrea [19]. 
In this study we show that rescaled renal biomarkers contain important diagnostic information about 
kidney function that can easily be interpreted in terms of 'normal' (healthy) or 'abnormal' (diseased) 
using the upper limit of 1.33 (=97.5thPct). We also wanted to investigate how mGFR evolved with age 
in the subgroup defined by renal biomarkers <1.33. Finally, we wanted to check the consistency 
between this fixed reference interval [0.67-1.33] to diagnose kidney function in terms of 
normal/abnormal and the use of a fixed or age-dependent threshold for mGFR. 
 
2.  METHODS AND PARTICIPANTS  
2.1.     Participants 
The current retrospective analysis collected data from 12 cohort studies. Among the 12 cohorts five 
[25-29] prospectively investigated the use of Scr and ScysC-based eGFR-equations for diagnosing 
chronic kidney disease. Eleven of the 12 cohorts, including n=6132 subjects, have been presented in 
detail elsewhere [19]. An additional cohort of healthy and kidney diseased subjects from Slovenia 
(n=134), has been included to increase the sample size for the [20-40] year age-range. The paediatric 
data from Lyon (n=259 children with 695 measurements) and adult data from the CRIC cohort (n=674 
adults with 1534 measurements) were also included in the current analysis. An additional number of 
adult patients from Paris and from Lyon were included to increase the sample size, especially for the 
[20-40] year age range. The data were anonymized and centralized for this study, which received IRB 
approval from Leuven University Hospital, Belgium. In total n=8584 participants, with data for mGFR, 
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standardized Scr and ScysC, age and gender were included. 
2.2.      Measurement methods 
A summary of the methods used in the different collaborating centres is given in Table 1 and have 
been previously described (except for Slovenia) in detail [19]. Direct GFR measurement was 
performed with different reference methods, as described before [18-19]. Scr was measured with 
assays traceable to IDMS, re-calculated to IDMS (CRIC study), or directly with IDMS [27] in all studies. 
ScysC was measured with assays that were calibrated against the certified ERM-DA471/IFCC 
standard or the results were recalculated to the certified reference standard [30]. The rescaling values 
for ScysC have been introduced in a previous study [19] and are further justified reference [31]. 
2.3.     Statistical analysis 
The data are presented as means and standard deviations or with 95% confidence intervals. 
Sensitivity (S) and specificity (Sp) are defined as: 
       TP                       TN 
S =--------    and   Sp = -------- 
      TP+FN                TN+FP 
 
With TP = True Positive, TN = True Negative, FP = False Positive and FN = False Negative. 
 
To define TP, TN, FP and FN, the healthy and diseased groups have to be defined, as well as the 
positivity and negativity of the test result. For this analysis, we used the total cohort of 8584 subjects, 
subdivided in age-decades. We here present three different scenarios: 
 
In the first scenario, measured GFR is used to define the kidney status in terms of 'healthy' or 
'diseased' based on the currently recommended fixed cutoff (COF) of 60mL/min/1.73m2. In this 
scenario, a true positive (TP) test result is obtained when (Scr/Qcrea+ScysC/QcysC)/2>1.33 in the 
subgroup with mGFR<COF=60mL/min/1.73m2. A true negative (TN) test result is obtained when 
(Scr/Qcrea+ScysC/QcysC)/2<1.33 in the subgroup with mGFR>COF=60mL/min/1.73m2. We here 
combine the rescaled biomarkers by taking the mean of both into one criterion. We can do this, as 
both rescaled biomarkers are evaluated on the same common "normalized" scale. It has been shown 
recently that using the combination of biomarkers increases the precision of the eGFR-equation 
significantly [18-19, 26, 32-33]. Therefore, diagnosing kidney disease based on the combined rescaled 
biomarkers is likely to be more accurate. Additionally, we have repeated this analysis for the single 
rescaled biomarkers in reference [31]. 
 
In the second scenario, measured GFR is used to define the kidney status in terms of 'healthy' or 
'diseased' based on an age-dependent threshold or cut-off (COAD), which we here define as: 
COAD = 107.3/1.33 [x 0.988(Age-40) when Age > 40 years]  
 
This threshold equals 107.3/1.33=80.7mL/min/l.73 m2 for ages <40 years, and then the threshold 
gradually declines with age (e.g. at the age of 65 years, the threshold becomes 59.7≈ 
60mL/min/1.73m2; at the age of 80 years, the threshold becomes 49.8≈ 50mL/min/1.73m2). The 
decrease in GFR with age has been well described even in healthy subjects [34-36]. The age-
dependent threshold, presented here, is based on the FAS-equation with Scr/Qcrea=ScysC/QcysC=1.33, 
the upper reference limit for the rescaled renal biomarkers [18-19] and has been introduced as an age-
dependent threshold for GFR in a recent publication [37].  
TP is here defined as (Scr/Qcrea+ScysC/QcysC)/2>1.33 in the subgroup with mGFR<COAD. TN is 
defined as (Scr/Qcrea+ScysC/QcysC)/2<1.33 in the subgroup with mGFR≥COAD. 
 
In the third scenario, we define kidney status in terms of 'healthy' or 'diseased' based on the rescaled 
renal biomarkers, which is the setting closest to clinical routine, as mGFR is usually not available. The 
kidney function is considered 'normal', or 'healthy', when the renal biomarkers are within the reference 
interval, or, when the average of both rescaled renal biomarkers is <1.33. Thus, when 
(Scr/Qcrea+ScysC/QcysC)/2>1.33, the kidney function is considered 'abnormal' or 'diseased'. To define 
TP and TN we now use mGFR (which is here available for the purpose of the study) as the 
reconfirming test result. As in the first and second scenario, we can use the fixed threshold of 
60mL/min/1.73m2 and the age-dependent threshold COAD. In other words, in the third scenario we turn 
things around by changing the roles of mGFR and the biomarkers in the definitions of TP, TN, FP and 
FN. Hereby we want to test the hypothesis whether biomarkers and mGFR can be used 
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interchangeably to diagnose and define kidney status. Therefore, we evaluate S and Sp versus age for 
the scenarios 1 compared to scenario 3 (with fixed cutoff for mGFR), and for scenario 2 versus 
scenario 3 (with age-dependent cutoff for mGFR). All analysis were done in SAS 9.4 (SAS Institute 
Inc., Cary, NC, USA). 
3. RESULTS 
3.1.       Patient characteristics 
Mean (±SD) for age, mGFR, rescaled Scr and ScysC are summarized for all individuals of the twelve 
contributing cohorts in Table 2. 
3.2.        Rescaled renal biomarkers within the reference interval and their 
relation with mean measured GFR 
There were n=4749 subjects exhibiting both rescaled biomarkers within the common reference interval 
[0.67-1.33]. They had a mean age of 55.0 years (SD=17.8) and mean mGFR of 88.6 (SD=19.6) 
mL/min/1.73m2. Table 3 presents an overview of the results per age-decade for this subgroup of 
patients. We also observe overall mean rescaled biomarker values close to '1.00', in each age-group, 
corresponding to the mean rescaled biomarker value for healthy people. Interestingly, the mean 
mGFRs in the different age-decades are very similar to the results described in the meta-analysis in 
healthy potential kidney donors [38]. 
In the next part of the results section we test the possibility to interchangeably use the renal 
biomarkers with fixed threshold of 1.33 and measured GFR with fixed threshold of 60mL/min/1.73m2 or 
with the previously defined age-dependent threshold. 
3.3.        Disease status defined by fixed mGFR threshold of 60mL/min/1.73mz 
We here combine the first scenario (=fixed threshold for mGFR) with the third scenario (=fixed 
threshold for rescaled renal biomarkers). We present the frequency of observations with renal 
biomarkers below and above 1.33 in the subgroups defined by mGFR< and >60mL/min/1.73m2 (Table 
4 and Figure 1). 
For children and older adults, sensitivity and specificity deviate largely depending on the definition of 
kidney status (either based on the rescaled renal biomarkers or on the fixed threshold of mGFR). For 
example, for children aged between 2 and 10 years, all patients with mGFR<60 have biomarker 
values >1.33 (S=28/28=100%), but only about 159 out of 218 (Sp = 73%) children with mGFR ≥60 
have biomarker values <1.33. Conversely, in older adults, aged 80-90, we observe that 182/(94+182) 
(S=66%) of the patients with mGFR<60 have biomarker values >1.33 and 153/(153+4) (Sp=97.5%) 
with mGFR≥60 having biomarker values ≤1.33. This analysis shows the lack of consistency or 
agreement in defining or diagnosing kidney disease based on the rescaled renal biomarker reference 
intervals and measured GFR combined with the fixed threshold of 60mL/min/1.73m2. 
3.4.       Disease status defined by an age-dependent threshold of mGFR 
Here, we combine the second scenario (=age-dependent threshold for mGFR) with the third scenario 
(=fixed threshold for the normalized renal biomarkers). We present the frequency of observations with 
normal and abnormal renal biomarkers in the subgroups defined by mGFR< and ≥COAD (Table 4). 
Sensitivity and specificity are nearly equal for all age-categories and close to 90% (Figure 2). This 
observation shows that when an age-dependent mGFR threshold is used to define the renal status as 
healthy or diseased, rescaled renal biomarkers and measured GFR give consistent results. 
4. DISCUSSION 
In this study we have evaluated the diagnostic value of Scr and ScysC as single renal biomarkers (see 
also the reference [31]) and by combining them. We used reference intervals of both renal biomarkers 
to diagnose kidney function as 'healthy' or 'diseased'. This was done by rescaling the biomarkers with 
appropriate rescaling factors: Qcrea for Scr and QcysC for ScysC. Rescaling renal biomarkers reveals 
several interesting and important properties, which are valid for both Scr/Qcrea and ScysC/QcysC. The 
rescaled biomarkers are independent of age and sex, and can thus be used for children, adolescents, 
adults and older adults. The rescaled biomarker is normally distributed with a mean of '1'. Therefore, 
the rescaled biomarker can, on average, be interpreted as follows: the further the value deviates from 
'1' the more the patient's kidney function deviates from the kidney function of the average healthy 
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subject. Outside the reference interval [0.67-1.33] the rescaled biomarker values are abnormal. Our 
analysis shows that in the subgroup of patients with rescaled biomarkers within the range of [0.67-
1.33], the mean measured GFR remains constant until the age of 40 years and then starts to decline 
with age. The identical phenomenon, that measured GFR remains constant until 40 years of age, and 
then starts to decline, was also observed in several studies with mGFR in healthy living kidney donors 
[39-43] and summarized in a recent meta-analysis on mGFR of living kidney donors, without 
information on renal biomarkers [38]. The fact that these 'healthy' mGFR-age profiles, are identical in 
the current study and in the previous meta-analysis, shows that 'healthy' kidney function can be 
diagnosed by rescaled biomarkers within the reference range. Interestingly, the rescaled biomarkers in 
the 'healthy' subgroup of the current analysis do not show an age-dependency, but remain 
approximately constant and, on average, equal to '1' during the complete lifetime. The present data 
therefore reconfirm the hypothesis that rescaled biomarkers are independent of age and gender (see 
also reference [31] for more detailed information on rescaled renal biomarkers and their relation with 
measured GFR). 
Measured GFR is the reference method to define kidney function. However, there is controversy about 
the thresholds to define 'healthy' or 'diseased' status of the kidney [34-36]. A necessary requirement of 
the current recommendation for CKD Stage 3 is that mGFR is < 60mL/min/1.73m2. In clinical practice, 
measured GFR is mostly unknown, as measuring GFR is not routinely performed. On the other hand, 
biomarkers are more easily obtained as this requires only one blood sample of the patient. As 
reference intervals of these rescaled biomarkers are available ([0.67-1.33]) it could be expected that 
these would correlate well with reference intervals for measured GFR. In the present study, we have 
confirmed that this is indeed the case, on condition that reference intervals for measured GFR are 
age-dependent. The present analysis shows that individuals above the age of 40 years, with 
biomarkers within the reference range of [0.67 - 1.33], have measured GFR that declines with age. 
Using biomarkers instead of mGFR to detect impaired kidney function would imply that sensitivity (S) 
and specificity (Sp), based on disease status as defined by the renal biomarkers, or as defined by 
measured GFR, are similar on average, when both definitions are used interchangeably. Ideally, S and 
Sp should be 100% and it should not make a difference which criterion (biomarkers or mGFR) is used 
to define kidney function (healthy or diseased) and which criterion is used to define the test result 
(positive or negative, based on a threshold). We have here demonstrated in a population of 8584 
individuals aged 1 to 95 that this interchangeability is true, with S and Sp close to 90% for all age-
groups, when an age-dependent threshold formGFR is used. We also evaluated the correspondence 
between the renal biomarker threshold of 1.33 and the measured GFR threshold of 60mL/min/1.73m2. 
We observed large deviations between S (or Sp) for children and for older adults. This confirms that 
the use of renal biomarkers and mGFR do not correspond well when a fixed mGFR threshold for the 
definition of kidney disease is used, in agreement with earlier suggestions for an age-calibrated 
definition of mGFR-categories [34,44]. When the here defined age-dependent threshold for mGFR is 
used, the S and Sp remain close to 90% for all ages, including children and older adults. The fact that 
S and Sp do not equal 100% is most likely due to variability in the measured GFR results (different 
methods), variability in the biomarker assay results (different tests, intra-test variability) and non-GFR 
determinants. 
The major strengths of our study are the large sample size and wide age-range, allowing statistical 
analysis per age-decade, the wide variety of measured GFR methods, and the use of calibrated 
assays for both biomarkers. Several limitations deserve attention. First, the participating study cohorts 
included only white participants. Second, we were not able to detect the influence of non-GFR 
determinants on the rescaled biomarkers' performance to diagnose renal impairment on an individual 
basis. Third, in contrast to measured GFR, rescaled/normalized biomarkers are not able to detect 
renal hyperfiltration. Fourth, in special populations like patients with abnormal muscle mass, chronic 
inflammation, under long-term steroid therapy, with oncologic diseases that go along with high cell 
turn-over, rescaled biomarkers have the same downside like traditional (non-rescaled) biomarkers or 
estimating equations and mGFR should be considered. 
This multi-cohort study allows to determine general trends but physicians should always consider the 
individual patient's characteristics when making a final decision about his/her renal function [45]. We 
would also like to emphasize that our current work is focusing on 'detection' of impaired renal function, 
not on estimating GFR. 
5. CONCLUSION 
There is a consistent correspondence between rescaled biomarkers within the reference interval and 
the course of mean mGFR with age in healthy subjects, highlighting the fact that from the age of 40 
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years onwards mean mGFR in healthy subjects declines with age. The rescaled renal biomarkers 
show excellent diagnostic performance to detect impaired kidney function, across all ages, 
corresponding with an age-dependent threshold for mGFR . 
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TABLES AND FIGURES 
Table 1: Overview of the methods for mGFR, Scr and ScysC in the 12 cohorts included for analysis 
 
Origin mGFR Scr SCysC 
Leuven, Belgium 51Cr-EDTA (4 points) Creatinine Plus, Roche enzym. Roche PETIA (Tina quant 
® Gen2) 
Lyon, France Inulin* Creatinine Plus, Roche enzym. Siemens PENIA 
(2 cohorts) iohexol (3 points)   
Maribor, 51Cr-EDTA (4 points) Creatinine Plus, Roche enzym. Siemens PENIA 
Slovenia    
Saint-Etienne, Iohexol (2 points) Enzymatic, Orthoclinical Diagn. Siemens PENIA [29] 
France    
Paris, France 51Cr-EDTA* Enzymatic, Siemens Siemens PENIA 
CRIC, USA 125l-iothalamate* Calculated back to Creatinine Calculated back to 
Siemens 
  Plus, Roche enzym. PENIA 
Troms0, Norway Iohexol (1 point) Creatinine Plus, Roche enzym Gentian PETIA [28] 
Rochester, USA lothalamate* Creatinine Plus, Roche enzym. Siemens PENIA [25] 
(2 cohorts)    
Berlin, Germany Iohexol (8 points) Creatinine Plus, Roche enzym. Siemens N-Latex® PENIA 
[26] 
Kent, UK Iohexol (3 points) IDMS Siemens PENIA [27] 
For mGFR, * = urinary and plasma clearance, all other methods are plasma clearance only. mGFR = 
measured glomerular filtration rate; Scr = serum creatinine; ScysC = serum cystatin C 
 
Table 2: summary of patient characteristics of the 12 cohorts (MeaniSD) ordered by mean age 
Data Origin N Age (years) mGFR 
(mL/min/1.73m2) 
SCr/Qcrea ScysC/QcysC 
Leuven (Belgium) 114 8.8 ±5.5 89.2 ±21.5 1.17 ±0.57 1.22 ±0.42 
Lyon (France) 695 12.7 ±3.8 84.7 ±32.7 1.37 ±0.60 1.52 ±0.62 
Maribor (Slovenia) 134 30.5 ±6.9 75.8 ±46.5 2.40 ±2.13 1.91 ±4.41 
Saint-Etienne (France) 203 48.7 ± 10.3 94.7 ± 24.4 1.01 ±0.22 1.09 ±0.28 
Paris (France) 1371 51.9 ± 14.4 65.5 ±27.4 1.62 ±0.90 1.65 ±0.90 
Lyon (France) 852 51.8 ±14.4 77.5 ±29.3 1.29 ±0.61 1.37 ±0.64 
CRIC (USA) 1534 58.6 ± 12.3 49.9 ±22.2 2.02 ±0.76 1.71 ±0.67 
Troms0 (Norway) 1627 58.1 ±3.8 91.7 ±14.4 0.95 ±0.14 0.90 ±0.14 
Rochester CKD (USA) 687 64.8 ± 8.8 80.4 ±21.3 1.08 ±0.26 1.01 ±0.26 
Rochester KFC (USA) 406 65.9 ±9.2 79.5 ±20.7 1.05 ±0.19 0.97 ±0.20 
Berlin (Germany) 567 78.5 ±6.2 60.3 ±16.4 1.22 ±0.43 1.21 ±1.11 
Kent (UK) 394 80.4 ±4.6 51.5 ±18.8 1.62 ±0.75 1.52 ±0.64 
Total 8584     
N = total number of participants; mGFR = measured glomerular filtration rate; Scr = serum creatinine; 
(Qcrea = normalization factor for Scr; ScysC = serum cystatin C; QcysC = normalization factor for ScysC 
 
Table 3: overview of the mean mGFR, mean rescaled Scr and mean rescaled ScysC (with 95% CI) for 
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246 135 [2-10[ 6.5 0.99 [0.96-1.02] 1.07 [1.05-1.10] 107.0 [103.2-110.9]  
599 245 [10-20[ 14.7 0.99 [0.97-1.01] 1.07 [1.05-1.09] 104.6 [101.7-107.5]  
227 113 [20-30[ 25.6 1.00 [0.97-1.04] 1.00 [0.97-1.03] 100.3 [96.4-104.2] 106.7 [104.6-108.9] 
539 277 [30-40[ 35.0 1.01 [0.99-1.02] 0.95 [0.94-0.97] 102.4 [100.2-104.6] 104.9 [102.8-107.0] 
801 407 [40-50[ 44.9 1.01 [0.99-1.03] 0.97 [0.96-0.99] 95.6 [93.9-97.3] 99.0 [96.5-101.6] 
2131 1474 [50-60[ 55.3 0.97 [0.96-0.98] 0.92 [0.91-0.93] 91.8 [91.0-92.6] 91.1 [88.2-94.1] 
2271 1255 [60-70[ 63.4 0.99 [0.98-1.00] 0.97 [0.96-0.97] 85.8 [84.9-86.7] 84.0 [79.5-88.5] 
1285 618 [70-80[ 74.6 1.04 [1.03-1.05] 0.97 [0.96-0.98] 72.1 [71.0-73.1] 69.4 [66.1-72.7] 
433 211 [80-90[ 83.1 1.05 [1.03-1.07] 1.05 [1.03-1.07] 65.6 [63.9-67.2]  
52 14 >90 91.9 1.07 [0.98-1.16] 1.18 [1.12-1.23] 52.7 [47.6-57.7]  
8584 4749       
n "normal" = number of subjects with both rescaled biomarkers within the common reference interval 
of [0.67 - 1.33]. mGFR = measured glomerular filtration rate; Scr = serum creatinine; (Qcrea = 
normalization factor for Scr; ScysC = serum cystatin C; QcysC = normalization factor for ScysC; 
 
Table 4: Frequency of patients with rescaled biomarkers below and above 1.33 in the subgroups 

























[2-10[ 0 159 14 145 159 28 59 67 20 87 246 
[10-20[ 1 317 38 280 318 152 129 245 36 281 599 
[20-30[ 3 131 21 113 134 73 20 83 10 93 227 
[30-40[ 1 331 41 291 332 151 56 191 16 207 539 
[40-50[ 11 474 69 416 485 233 83 298 18 316 801 
[50-60[ 34 1587 81 1540 1621 412 98 465 45 510 2131 
[60-70[ 82 1355 92 1345 1437 704 130 700 134 834 2271 
[70-80[ 174 557 65 666 731 519 35 472 82 554 1285 
[80-90[ 94 153 16 231 247 182 4 160 26 186 433 
>90 15 3 2 16 18 34 0 30 4 34 52 
Total 415 5067 439 5043 5482 2488 614 2711 391 3102 8584 
mGFR = measured glomerular filtration rate; Scr = serum creatinine; Qcrea = normalization factor for 




Figure 1a: Sensitivity is presented by age-category (Table 4). Solid circles represent the first scenario 
in which a true positive test result is defined as (Scr/Qcrea+ScysC/QcysC)/2>1.33 in the subgroup with 
mGFR<60mL/min/1.73m2. The open circles represent the third scenario in which a true positive test 
result is defined as mGFR<60mL/min/1.73m2 in the subgroup with (Scr/Qcrea+ScysC/Qcysc)/2>1.33. 
Error bars are defined as  
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Figure 1b: Specificity is presented by age-category (Table 4). Solid circles represent the first scenario 
in which a true negative test result is defined as (Scr/Qcrea+ScysC/QcysC)/2 ≤1.33 in the subgroup with 
mGFR≥60mL/min/1.73m2. The open circles represent the third scenario in which a true negative test 
result is defined as mGFR≥60mL/min/1.73m2 in the subgroup with (Scr/Qcrea+ScysC/Qcysc)/2≤1.33. 
Error bars are defined as  
 
 
Figure 2a: Sensitivity is presented by age-category (Table 4). Solid circles represent the second 
scenario in which a true positive test result is defined as (Scr/Qcrea+ScysC/QcysC)/2>1.33 in the 
subgroup with mGFR<GFRCO∙ The open circles represent the third scenario in which a true positive 
test result is defined as mGFR<GFRco in the subgroup with (Scr/Qcrea+ScysC/Qcysc)/2>1.33. Error bars 
are defined as  
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Figure 2b: Specificity is presented by age-catgory (Table 4). Solid circles represent the second 
scenario in which a true negative test result is defined as (Scr/Qcrea+ScysC/QcysC)/2 ≤1.33 in the 
subgroup with mGFR≥GFRCO∙ The open circles represent the third scenario in which a true negative 
test result is defined as mGFR ≥GFRco in the subgroup with (Scr/Qcrea+ScysC/Qcysc)/2<1.33. Error 
bars are defined as  
 
